MedTrace Logo

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

NCT00630695 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2012-01-16

No results posted yet for this study

Summary

Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study

Conditions

  • Lymphocele

Interventions

DRUG

Lanreotide LP 90

Lanreotide LP 90

DRUG

Placebo lanreotide

Placebo

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • University Hospital, Limoges

    lead OTHER

Principal Investigators

  • Yves Aubard, MD, PhD · University Hospital, Limoges

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-06-30
Completion
2011-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00630695 on ClinicalTrials.gov